Key Points
- CEO Martine Rothblatt sold 9,500 United Therapeutics shares at an average price of $502.35, generating approximately $4.77 million. She retains 324,443 shares, and the transaction reduced her ownership by 2.84%.
- United Therapeutics reported quarterly EPS of $7.27, beating estimates of $6.86, while revenue of $783.3 million fell short of expectations and declined 1.9% year over year.
- Analysts maintain a generally positive outlook, with 11 Buy ratings and two Holds producing a consensus “Moderate Buy” rating and a $646 price target. Institutional investors own 94.08% of the company.
United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) CEO Martine Rothblatt sold 9,500 shares of the business's stock in a transaction that occurred on Thursday, September 10th. The shares were sold at an average price of $502.35, for a total value of $4,772,325.00. Following the transaction, the chief executive officer owned 324,443 shares of the company's stock, valued at approximately $162,983,941.05. This trade represents a 2.84% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.
United Therapeutics Trading Down 1.3%
United Therapeutics stock opened at $497.11 on Friday. United Therapeutics Corporation has a 12-month low of $396.12 and a 12-month high of $609.35. The firm has a market capitalization of $21.32 billion, a price-to-earnings ratio of 17.79, a P/E/G ratio of 2.51 and a beta of 0.56. The firm has a 50 day moving average of $520.91 and a 200 day moving average of $540.30.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share for the quarter, beating the consensus estimate of $6.86 by $0.41. The business had revenue of $783.30 million for the quarter, compared to the consensus estimate of $804.65 million. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The company's revenue for the quarter was down 1.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned $6.41 earnings per share. On average, analysts predict that United Therapeutics Corporation will post 26.33 EPS for the current year.
Analyst Ratings Changes
A number of research firms recently weighed in on UTHR. Morgan Stanley set a $515.00 target price on shares of United Therapeutics in a research note on Thursday, August 6th. JPMorgan Chase & Co. increased their price target on United Therapeutics from $685.00 to $687.00 and gave the stock an "overweight" rating in a research note on Thursday, July 23rd. Royal Bank Of Canada decreased their price target on United Therapeutics from $704.00 to $677.00 and set an "outperform" rating on the stock in a report on Thursday, August 6th. Weiss Ratings downgraded United Therapeutics from a "buy (b)" rating to a "buy (b-)" rating in a research report on Thursday, August 27th. Finally, TD Cowen reaffirmed a "buy" rating on shares of United Therapeutics in a research note on Thursday, May 21st. Eleven research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $646.00.
Check Out Our Latest Research Report on UTHR
Hedge Funds Weigh In On United Therapeutics
A number of hedge funds and other institutional investors have recently modified their holdings of the stock. California State Teachers Retirement System increased its holdings in United Therapeutics by 55,526.2% in the 2nd quarter. California State Teachers Retirement System now owns 33,288,952 shares of the biotechnology company's stock valued at $18,036,953,000 after acquiring an additional 33,229,108 shares during the last quarter. BlackRock Inc. purchased a new position in shares of United Therapeutics during the second quarter valued at about $2,868,735,000. Avoro Capital Advisors LLC grew its position in shares of United Therapeutics by 17.3% during the fourth quarter. Avoro Capital Advisors LLC now owns 2,606,060 shares of the biotechnology company's stock valued at $1,269,803,000 after purchasing an additional 383,838 shares in the last quarter. Wellington Management Group LLP increased its holdings in shares of United Therapeutics by 74.5% in the fourth quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company's stock worth $1,189,617,000 after purchasing an additional 1,042,711 shares during the last quarter. Finally, AQR Capital Management LLC increased its holdings in shares of United Therapeutics by 29.9% in the fourth quarter. AQR Capital Management LLC now owns 1,281,699 shares of the biotechnology company's stock worth $624,508,000 after purchasing an additional 295,221 shares during the last quarter. Institutional investors own 94.08% of the company's stock.
About United Therapeutics
(
Get Free Report)
United Therapeutics Corporation is a biotechnology company focused on developing and commercializing therapies for serious and life-threatening conditions, with a primary emphasis on pulmonary arterial hypertension (PAH). The company's products are designed to improve pulmonary blood flow and reduce the effects of this progressive disease.
United Therapeutics' PAH portfolio includes Remodulin (treprostinil) injection, Orenitram (treprostinil) extended-release tablets, and Tyvaso (treprostinil), which is available as an inhalation solution and as the Tyvaso DPI dry-powder inhaler.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
